The introduction of B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy (CAR-T) in clinical practice has radically transformed the treatment paradigm of multiple myeloma (MM). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.